Fusion Antibodies plc

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. It has a collaboration agreement with the National Cancer Institute for the use of OptiMAL for discovery of novel antibodies against targets selected by NCI. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.